CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Dr. Nastoupil on Challenges Faced With CAR T-Cell Therapy in DLBCL

February 3rd 2021

Loretta J. Nastoupil, MD, discusses challenges faced with CAR T-cell therapy in patients with diffuse large B-cell lymphoma.

Dr. Hwu on the Uptake of Cellular Therapy in Oncology

February 2nd 2021

Patrick Hwu, MD, discusses the uptake of cellular therapy in the treatment of patients with cancer.

Capitalizing on Cellular Therapies in Lymphoma and Myeloma

January 18th 2021

In our exclusive interview, Dr. Kansagra, Dr. D’Souza, and Dr. Dholaria provided an in-depth look into the current state of cellular therapy in hematologic malignancies, the benefits and drawbacks of approved and investigational products, and new constructs for CAR T in multiple myeloma and lymphoma.

Dr. Shah on the Safety of a Novel Dual-Targeted CAR T-Cell Therapy in Non-Hodgkin Lymphoma

January 14th 2021

Nirav Shah, MD, MCW, discusses the safety profile of an anti-CD20/anti-CD19 CAR T-cell therapy under investigation in the treatment of patients with non-Hodgkin lymphoma.

Dr. Frigault on Toxicity Differences Among CAR T-Cell Products in Leukemias, Lymphomas

January 11th 2021

Matthew Frigault, MD, discusses differences in the toxicities experienced with CAR T-cell products used in the treatment of patients with leukemias and lymphomas.

Brexucabtagene Autoleucel Provides New Option for Patients With R/R MCL

January 8th 2021

Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.

Dr. Lin on the Emergence of CAR T-Cell Therapy in Multiple Myeloma

January 7th 2021

Yi Lin, MD, PhD, discusses the emergence of CAR T-cell therapy in multiple myeloma.

MCL Landscape Adapts to Changes After CAR T-Cell Therapy Approval

January 6th 2021

James Gerson, MD, discusses the introduction of CAR T-cell therapy to the mantle cell lymphoma armamentarium and how induction therapy followed by stem cell transplant has maintained a role.

Dr. Lin on Patient Characteristics From the CRB-401 Study of Ide-Cel in Myeloma

January 5th 2021

Yi Lin, MD, PhD, discusses the characteristics of patients who were included in the CRB-401 study examining the CAR T-cell product idecabtagene vicleucel in multiple myeloma.

Liso-Cel BLA for Relapsed/Refractory LBCL Remains Under FDA Review

January 4th 2021

January 4, 2021 - The biologics license application for the CAR T-cell product lisocabtagene maraleucel in adult patients with relapsed/refractory large B-cell lymphoma following at least 2 previous therapies continues to be under regulatory review by the FDA, and a decision on the application has not yet been reached.

Dr. Siddiqi on the Rationale to Evaluate CAR T-Cell Therapy in CLL

December 23rd 2020

Tanya Siddiqi, MD, discusses the rationale to evaluate CAR T-cell therapy in chronic lymphocytic leukemia.

Rapid Readouts: Phase 1b/2 CARTITUDE-1 Study

December 23rd 2020

FDA Approval Sought for Cilta-Cel in Relapsed/Refractory Multiple Myeloma

December 21st 2020

December 21, 2020 - A rolling submission of the biologics license application for the BCMA-directed CAR T-cell product ciltacabtagene autoleucel for use in adults with relapsed/refractory multiple myeloma has been initiated to the FDA.

Liso-Cel Proves to Be Highly Active, Tolerable in Relapsed/Refractory MCL

December 17th 2020

December 17, 2020 - Lisocabtagene maraleucel exhibited promising antitumor activity with low rates of grade 3 or higher cytokine release syndrome and neurotoxicity in patients with relapsed/refractory mantle cell lymphoma.

KTE-X19 Approved in Europe for Relapsed/Refractory MCL

December 17th 2020

December 17, 2020 — The European Commission has granted a conditional marketing authorization to the CD19-targeted CAR T-cell therapy KTE-X19 for use in adult patients with relapsed or refractory mantle cell lymphoma who had previously received 2 or more lines of systemic therapy including a BTK inhibitor.

Dr. Kahl on Remaining Challenges With CAR T-Cell Therapy in DLBCL

December 8th 2020

Brad S. Kahl, MD, discusses remaining challenges with CAR T-cell therapy in diffuse large B-cell lymphoma.

Liso-Cel Shows Durable Responses in Patients with Relapsed/Refractory CLL/SLL

December 8th 2020

December 7, 2020 - In high-risk patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, lisocabtagene maraleucel treatment resulted in a high rate of undetectable minimal residual disease with rapid and durable responses

Allogeneic Off-the-Shelf UCART22 Product Shows Early Activity, Tolerability in Relapsed/Refractory CD22+ B-Cell ALL

December 6th 2020

December 6, 2020 - UCART22, an allogeneic off-the-shelf CD22-directed T-cell product, showed no unexpected toxicities at 2 dose levels and had early signs of activity in adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia.

Cilta-Cel Confers 97% ORR in Relapsed/Refractory Multiple Myeloma

December 6th 2020

December 5, 2020 - Treatment with the CAR T-cell therapy ciltacabtagene autoleucel led to a high response rate and an acceptable safety profile at the recommended phase 2 dose in patients with relapsed or refractory multiple myeloma.

Novel CAR Engineering Overcomes Resistance in Large B-Cell Lymphoma With CD58 Loss

December 5th 2020

December 5, 2020 - Engineering chimeric antigen receptors T cells to overcome CD58 loss may provide a path forward for patients with large B-cell lymphomas who do not respond to treatment with immunotherapy.